MENU
+Compare
LYRA
Stock ticker: NASDAQ
AS OF
Oct 17 closing price
Price
$6.90
Change
-$0.25 (-3.50%)
Capitalization
11.35M

LYRA Lyra Therapeutics Inc Forecast, Technical & Fundamental Analysis

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients... Show more

LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for LYRA with price predictions
Oct 17, 2025

LYRA's Stochastic Oscillator dives oversold zone

The Stochastic Oscillator for LYRA moved into oversold territory on October 17, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for LYRA crossed bullishly above the 50-day moving average on October 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LYRA advanced for three days, in of 230 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 140 cases where LYRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for LYRA moved out of overbought territory on October 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on October 17, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on LYRA as a result. In of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LYRA turned negative on October 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

LYRA moved below its 50-day moving average on October 17, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LYRA broke above its upper Bollinger Band on October 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.998) is normal, around the industry mean (24.226). P/E Ratio (0.000) is within average values for comparable stocks, (54.529). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (11.834) is also within normal values, averaging (349.660).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LYRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a clinical-stage therapeutics company, which develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
480 Arsenal Way
Phone
+1 617 393-4600
Employees
145
Web
https://lyratherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MCBS26.330.56
+2.17%
MetroCity Bankshares
VG8.88-0.25
-2.74%
Venture Global Inc
GTE3.78-0.16
-4.06%
Gran Tierra Energy
SHFS3.78-0.17
-4.30%
SHF Holdings Inc
DGNX14.80-1.87
-11.22%
Diginex Limited

LYRA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LYRA has been loosely correlated with EYPT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if LYRA jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYRA
1D Price
Change %
LYRA100%
-3.47%
EYPT - LYRA
58%
Loosely correlated
+0.69%
VERA - LYRA
54%
Loosely correlated
+2.36%
KYMR - LYRA
51%
Loosely correlated
-1.04%
CLNN - LYRA
39%
Loosely correlated
+3.03%
ERAS - LYRA
34%
Loosely correlated
-4.35%
More